... not-for-profit publisher RSC Publishing announced... a new publication, Energy & Environmental Science...e will link all aspects of the chemical sciences b...n and storage, alternative fuel technologies, and ...l publishing topical reviews and original research...
... University of Toronto scientists have devised a t...cell by successfully mapping all 70,000 nucleosome...sformed into proteins and are critical indicators ...islow, a U of T Assistant Professor with the Banti...artment of Molecular Genetics, the team created a ...
...nosis of the temper and vital signs of the oceans ..., says a distinguished partnership of internationa...rine monitoring system within 10 years. , The Par...O) says warming seas, over-fishing and pollution a...sured to help society respond in a well-informed, ...
Other Biology News:Human safety, prosperity depend on better ocean observing system: Scientists 2Human safety, prosperity depend on better ocean observing system: Scientists 3Human safety, prosperity depend on better ocean observing system: Scientists 4Human safety, prosperity depend on better ocean observing system: Scientists 5Human safety, prosperity depend on better ocean observing system: Scientists 6Human safety, prosperity depend on better ocean observing system: Scientists 7Human safety, prosperity depend on better ocean observing system: Scientists 8(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5...Md., Oct. 28 Novavax, Inc.,(Nasdaq: NVAX ) a cli...Dr.,Rahul Singhvi, President and Chief Executive O...um 2008 at 8:30 am. (PT) on October 30, 2008 at th...inghvi will provide an,overview of the company,s s... to the live presentation can be accessed via the ...
...Mass., Oct. 28 Peptimmune, Inc., a privately,held...dent & CEO Thomas P.,Mathers will provide an updat... for PI-2301 in multiple sclerosis patients at the...008. The presentation will take place on Wednesday...om at the Palace Hotel in San Francisco. 2. O...
...British Columbia, Oct. 28 ,ProtoKinetix Inc. (OTC ...n,the research, development and commercialization ...announced today that OTC Financial Network,(OTCFN)...Corp. (NFC), has,issued a corporate profile on the... ProtoKinetix technology platform, its multiple co...
Other Biology Technology:Peptimmune Presentations at Upcoming Events 2OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc. 2OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc. 3...bulizers are available in two product models - the... two models is that the 6000AT+ includes a membran... aerosol for improved detection limits and reduced...on limits for a range of elements by 10-40 times. ...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related ...ailability of new radiolabeled ligands selected to...s a wide range of products and services for recept... state-of-the-art radioligands. If you do not find...
AMV RT HC 600 U from Invitrogen
...ding) was developed using a protein engineering ap... DNA binding pocket of wild-type DNase I. These ch...n for DNA. The result is a versatile enzyme that h...intain at least 50% of peak activity in solutions ...
Biology Products: